Completed PHASE1 INTERVENTIONAL 4-arm NCT00468819

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Open-label Multi-center Study of Magnetic Resonance Imaging (MRI) With 0.1 mmol/kg Body Weight (BW) Gadavist (1.0 M) to Assess Pharmacokinetics, Safety and Tolerability in Children.

Sponsor: Bayer

Conditions Magnetic Resonance Imaging

Interventions Gadobutrol (Gadavist, Gadovist, BAY86-4875)

Updated 7 times since 2017 Last updated: Jun 29, 2015 Started: May 31, 2007 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Magnetic Resonance Imaging and is currently completed. Bayer leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bonn, Germany , Dresden, Germany , Edmonton, Canada , Erlangen, Germany , Gothenburg, Sweden , Halle, Germany , Jena, Germany , Kiel, Germany , Leipzig, Germany , Stockholm, Sweden and 3 more locations